)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
ExpreS2ion Biotech
ExpreS2ion Biotech (EXPRS2) investor relations material
ExpreS2ion Biotech Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
ES2B-C001 enrolled 19 patients; 12 of 13 evaluable patients had at least a twofold anti-HER2 antibody increase, with no dose-limiting toxicities reported.
The Phase I primary readout is expected in Q1 2027; Phase II is targeted for H2 2027, subject to partnering and financing.
Q3 net loss was SEK 9.935m; cash was SEK 23.963m at 30 September, before SEK 19.3m in post-period gross financing proceeds.
Financial highlights
Q3 operating income was SEK 2.292m, flat YoY; net sales rose 286% to SEK 1.364m while other operating income fell 52% to SEK 0.928m.
Q3 operating costs rose 25% to SEK 15.052m; operating loss was SEK 12.760m versus SEK 9.746m, and net loss was SEK 9.935m versus SEK 8.445m.
9M net sales rose 37% to SEK 4.413m; operating income was SEK 20.707m versus SEK 8.674m.
9M operating costs were SEK 57.4m versus SEK 42.8m; 9M net loss narrowed 2% to SEK 29.226m from SEK 29.910m.
Q3 R&D spend was SEK 3.7m, up 56% YoY, reflecting ES2B-C001 trial and higher CMC costs.
Outlook and guidance
ES2B-C001 priming is expected to finish in Q4 2026; translational results are expected by year-end, database lock in February 2027 and primary readout in Q1 2027.
Proposed Phase II scope is 80–120 first-line HER2-positive metastatic breast cancer patients, with 24-month PFS as the readout; H2 2027 start depends on partner and funding.
Nipah toxicology and IND-enabling work is planned for 2027, with Phase I initiation thereafter, subject to clinical, regulatory, manufacturing, funding and partner factors.
VAC-087 and VAC-093 malaria trials are expected to complete in Q4 2026; BIO-005 completion is expected in Q2 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from ExpreS2ion Biotech
- Phase I antibody responses underpin a planned ES2B-C001 Phase II start in H2 2027.EXPRS2
26th Annual Biotech in Europe Forum - HER2+ breast cancer vaccine nears clinical trial as SEK 60M rights issue supports 2026 data goal.EXPRS2H C Andersen Capital Life Science Seminar
- Lead HER2-targeting vaccine nears clinical trials, backed by strong data and major partnerships.EXPRS2Stora Aktiedagarna Stockholm
- Advancing a first-in-class HER2 vaccine for breast cancer with strong preclinical and early clinical progress.EXPRS2H.C. Andersen Capital Institutional Seminar presentation
- First-in-class HER2 immunotherapy advances in trials, with major milestones expected by 2026.EXPRS2Aktiespararna Aktiedagen
- Promising HER2 vaccine shows durable immune response and clear path to Phase II.EXPRS2Sachs European Life Science Forum
- First-in-class HER2 immunotherapy shows promise in early trials, with major catalysts ahead.EXPRS2Økonomisk Ugebrev Life Science Investor Conference
- ES2B-C001 nears phase I, showing strong efficacy, safety, and commercial promise for HER2+ breast cancer.EXPRS2BioStock Life Science
- HER2-targeted VLP vaccine with strong preclinical results enters phase I trials in 2025.EXPRS2Biostock Life Science Summit
Next ExpreS2ion Biotech earnings date
Q4 202625 Feb, 2027
ExpreS2ion Biotech
Next ExpreS2ion Biotech earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops, produces, and delivers therapeutics or diagnostic proteins in Denmark and internationally. The company uses its expression system technology to offer services that include cell line development, screening of cell bank clones developed in the clients' host cell line of interest, analytical services comprising host cell line development, clone screening and base media optimization, process scale-up and GMP manufacturing. It also manufactures and distributes therapeutic proteins based on prokaryotic and eukaryotic expression systems using the GalXC protein expression system to EU/US chemical and health companies.